Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PANRETIN vs DEHYDRATED ALCOHOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Alitretinoin is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptors (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ). It modulates cell growth, differentiation, and apoptosis in both normal and malignant cells. In Kaposi sarcoma, it inhibits tumor cell proliferation and induces differentiation.
Dehydrated alcohol (ethanol) causes tissue necrosis by protein denaturation and cellular dehydration, leading to vascular thrombosis and ischemic infarction. It ablates nerve tissue by extracting lipids and precipitating proteins.
FDA-approved: Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi sarcoma,Off-label: Treatment of chronic hand eczema (oral formulation, not available in US)
FDA-approved for adjunctive therapy in the treatment of cystic thyroid nodules,Off-label: Neurolysis for celiac plexus block in pancreatic cancer pain,Off-label: Ablation of hepatocellular carcinoma,Off-label: Sclerotherapy for esophageal varices
Apply 0.1% gel topically to lesions twice daily.
Intravenous administration: 0.1-1 m L of sterile dehydrated alcohol (100% ethanol) injected directly into cystic lesions or tumors under imaging guidance. Maximum volume per injection: 1 m L, repeated up to 3 times per session depending on lesion size.
Mean terminal half-life of approximately 5-10 hours; clinical context: supports twice-daily topical application.
2-4 hours in most individuals at zero-order kinetics; terminal half-life is concentration-dependent due to saturation of alcohol dehydrogenase. Clinically, elimination rate is constant at 15-20 mg/d L/hour in non-tolerant individuals.
Metabolized primarily by CYP2C9, CYP3A4, and CYP2C8 to major metabolites (e.g., 4-oxo-alitretinoin, 9-cis-retinoic acid). Glucuronidation also contributes.
Primarily hepatic via alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH); minor metabolism via CYP2E1 at high concentrations.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine.
Ethanol is primarily eliminated by hepatic metabolism (90-98%) via alcohol dehydrogenase and aldehyde dehydrogenase, with 2-10% excreted unchanged in urine, breath, and sweat. Renal elimination is minor and variable.
>99% bound to plasma proteins, primarily albumin and lipoproteins.
Negligible (<5%); no specific binding proteins.
Not applicable for topical administration; systemic absorption is minimal with no established Vd.
0.5-0.7 L/kg, approximating total body water. Higher in females due to lower lean body mass.
Systemic bioavailability after topical application is <1% of applied dose.
Oral: ~80-100% due to rapid absorption from stomach and small intestine; IV: 100%.
No dose adjustment required for renal impairment.
No dosage adjustment required for renal impairment.
No dose adjustment recommended for hepatic impairment.
No specific Child-Pugh-based adjustments; use with caution in severe hepatic dysfunction due to potential accumulation.
Not indicated for pediatric patients below 18 years of age.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No specific dose adjustment; use with caution due to potential for increased skin sensitivity.
No specific dose adjustment; use with caution due to age-related comorbidities and potential for increased sensitivity.
Not applicable for topical formulation. Oral alitretinoin (not marketed in US) carries a boxed warning for teratogenicity and must not be used during pregnancy.
No FDA boxed warning exists for dehydrated alcohol. However, it should only be administered by physicians experienced in injection techniques for specific indications due to risk of tissue necrosis and nerve damage.
Teratogenicity: Avoid use during pregnancy; effective contraception required,Photosensitivity: Avoid excessive sun exposure,Local skin reactions: erythema, edema, peeling at application site,Hyperlipidemia: Monitor lipids in prolonged use,Pancreatitis: Risk in patients with hypertriglyceridemia,Hepatotoxicity: Monitor liver function tests,Pseudotumor cerebri: Discontinue if signs of intracranial hypertension
Risk of tissue necrosis and sloughing if extravasation occurs,Neurological injury if injected near nerves (e.g., peripheral nerve damage, paralysis),Hypotension and bradycardia during celiac plexus block,Alcohol intoxication and CNS depression if absorbed systemically,Use with caution in patients with liver disease or diabetes mellitus
Hypersensitivity to alitretinoin or any component of the formulation,Pregnancy (topical: use only if no safer alternative; oral: absolutely contraindicated)
Hypersensitivity to ethanol or any component of the formulation,Acute infection at the injection site,Uncorrectable coagulation abnormalities,Pregnancy (relative contraindication due to fetal alcohol spectrum disorders)
No known food interactions. Avoid concurrent use of other topical products on the same area.
No specific food interactions. However, avoid alcohol consumption for 24 hours post-procedure due to risk of additive CNS depression.
PANRETIN (alitretinoin) is a retinoid and is contraindicated in pregnancy. Category X: Animal studies have demonstrated teratogenic effects (craniofacial, cardiovascular, CNS abnormalities). First trimester exposure carries highest risk. Second and third trimester: risk of fetal retinoid syndrome (craniofacial dysmorphism, CNS anomalies, cardiovascular malformations). Effective contraception must be used.
First trimester: Data limited; alcohol is a known teratogen causing fetal alcohol spectrum disorders. Increased risk of congenital anomalies (e.g., heart defects, microcephaly) with high systemic exposure. Second trimester: Continued risk for growth restriction and neurodevelopmental abnormalities. Third trimester: Risk of growth retardation, preterm birth, and neurobehavioral deficits. Avoid systemic use; local injection for nerve block or ablation has minimal systemic absorption but caution advised.
No data on excretion in human milk. Retinoids are known to be excreted in animal milk. Because of potential for serious adverse reactions in nursing infants (teratogenicity, retinoid toxicity), breastfeeding is contraindicated during therapy and for at least 1 month after last dose.
Alcohol is excreted into breast milk; M/P ratio approximately 1.0. Chronic ingestion can impair infant motor development. Dehydrated alcohol for therapeutic injection likely results in negligible systemic levels; however, avoid breastfeeding immediately after procedure. Advise discarding milk for 2-3 hours post-procedure.
Contraindicated in pregnancy; no dose adjustments applicable. Ensure patient is not pregnant before initiating therapy.
No dose adjustment needed for localized injection; pharmacokinetics of ethanol unchanged in pregnancy. Avoid use as systemic agent; use alternative if possible.
Panretin (alitretinoin) gel is a topical retinoid indicated for cutaneous Kaposi sarcoma. Use gloves during application; avoid application to normal skin as it may cause irritation. Monitor for local adverse reactions like erythema, edema, and pain. Do not use concurrently with other topical agents on the same site.
Absolute ethanol (dehydrated alcohol) is used for neurolysis in celiac plexus block for pancreatic cancer pain and for ablation of certain soft tissue lesions. Administer slowly to avoid local toxicity. Inadvertent intravascular injection can cause immediate pain and tissue necrosis. Use ultrasound or CT guidance for accurate placement. Monitor for hypotension, pain, and transient alcohol intoxication. Contraindicated in patients with bleeding disorders or local infection.
Apply a thin layer only to Kaposi sarcoma lesions, avoiding healthy skin.,Wash hands thoroughly before and after application.,Do not cover with bandages or dressings unless instructed.,Expected side effects include redness, swelling, and pain at application site.,Avoid exposure to sunlight or tanning lamps; use sunscreen on treated areas.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
You may feel a temporary burning sensation at the injection site.,This medication is used to block pain signals from certain nerves.,Avoid alcohol consumption for 24 hours after the procedure to prevent additive effects.,Report any severe pain, bleeding, or signs of infection to your healthcare provider.,You may experience temporary dizziness or lightheadedness after the injection.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PANRETIN vs DEHYDRATED ALCOHOL, answered by our medical review team.
PANRETIN is a Topical Retinoid that works by Alitretinoin is a naturally occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptors (RARα, RARβ, RARγ, RXRα, RXRβ, RXRγ). It modulates cell growth, differentiation, and apoptosis in both normal and malignant cells. In Kaposi sarcoma, it inhibits tumor cell proliferation and induces differentiation.. DEHYDRATED ALCOHOL is a Sclerosing agent that works by Dehydrated alcohol (ethanol) causes tissue necrosis by protein denaturation and cellular dehydration, leading to vascular thrombosis and ischemic infarction. It ablates nerve tissue by extracting lipids and precipitating proteins.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PANRETIN and DEHYDRATED ALCOHOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PANRETIN is: Apply 0.1% gel topically to lesions twice daily.. The standard adult dose of DEHYDRATED ALCOHOL is: Intravenous administration: 0.1-1 m L of sterile dehydrated alcohol (100% ethanol) injected directly into cystic lesions or tumors under imaging guidance. Maximum volume per injection: 1 m L, repeated up to 3 times per session depending on lesion size.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PANRETIN and DEHYDRATED ALCOHOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PANRETIN is classified as Category C. PANRETIN (alitretinoin) is a retinoid and is contraindicated in pregnancy. Category X: Animal studies have demonstrated teratogenic effects (craniofacial, cardiovascular, CNS abnor. DEHYDRATED ALCOHOL is classified as Category C. First trimester: Data limited; alcohol is a known teratogen causing fetal alcohol spectrum disorders. Increased risk of congenital anomalies (e.g., heart defects, microcephaly) wit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.